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Objective: To investigate changes in fecal flora and multiple-dose pharmacokinetics with the oral antibiotics ceftibuten 
400 mg daily and cefpodoxime proxetil (CPX) 200 mg every 12 h, compared to amoxycillin/clavulanate 500/125 mg every 
8 h during and following 1 week of medication. 
Methods: In an open randomized triple crossover design, 18 (nine female, nine male) healthy volunteers received each 
drug for 7 days, followed by a ‘washout’ period of 4 weeks. Serum and urine levels of the substances were determined 
by bioassay, and for ceftibuten isomers by high-pressure liquid chromatography. Statistical analysis of quantitative 
aerobic and anaerobic cultures; of feces was performed, and P-lactamase activity was determined. 
Results: Ceftibuten showed a mean C, of 18.9 (SD 3.0) mg/L, a terminal half-life of 2.89 h, and an AUCtot of 100 (21.8) 
mg.h/L; protein binding was 631.7 (5.1)%, and accumulation was marginal. Cefpodoxime proxetil had a C,, of 1.92 (0.61) 
mg/L, a terminal half-life of 1.97 (0.42) h and an AUCtot of 10.8 (3.3) mg.h/L; no accumulation was seen. Amoxycillin and 
clavulanate had C,,, values of 7.15 (2.16) mg/L and 3.39 (1.31) mg/L, terminal half-life values of 1.03 (0.15) h and 0.93 
(0.17) h, AUCtot values of 20.0 (4.2) mg.h/L and 8.87 (3.10) mg.h/L, and there was no accumulation. Statistical analysis 
for ech microorganism in fecal1 samples showed significant differences between amoxycillin/clavulanate and the two 
third-generation cephalosporiris, but virtually no differences between ceftibuten and cefpodoxime proxetil. Eleven of 12 
volunteers reported loose stools (days 2-7, mean duration 4.4 (SD 2.7) days) with amoxycillin/clavulanate, but nobody 
during ceftibuten administration and one volunteer during cefpodoxime proxetil administration. 
Conclusions: Ceftibuten showed excellent and cefpodoxime favorable pharmacokinetic properties, with significantly 
less pronounced fecal flora changes and intestinal side effects compared to amoxycillin/clavulanate. The multiple 
crossover design allows powerful microbiological statistical analysis and pharmacokinetic parameter comparisons. 
Key words: Ceftibuten, cefpocloxime proxetil, amoxycillin/clavulanate, fecal flora, statistical analysis, pharmacokinetics, 
p-lactamase activity, triple crossover design 
INTRODUCTION 
Besides partially improved pharmacokinetic character- 
isitics, the main advantages of new oral cephalosporins 
over older derivatives are their broader spectra of in 
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vitro activity against Gram-positive and Gram-negative 
bacteria [1,2]. Ceftibuten, cefpodoxime proxetil and 
amoxycillin/clavulanate are widely used antibiotics for 
upper and lower respiratory as well as urinary tract 
infections. 
Ceftibuten is an orally active third-generation 
non-ester cephalosporin. It has broad in vitro anti- 
bacterial activity against the majority of Gram-negative 
pathogens, including Klebsiella spp., good activity 
against streptococci [2-51, marginal activity against 
penicillin-susceptible Streptococcus pneumoniae [3,6-91, 
and poor activity against Staphylococcus aureus. It shows 
an absorption rate between 75% and 90% [4,10] and, 
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though resistant to most broad-spectrum 0-lactamases, 
including those of many Enterobcteriaceae, it is cleaved 
by a 0-lactamase produced by Bacteroides spp. so that 
very little active substance is found in the colon [l l] .  
Cefpodoxime proxetil is a prodrug ester of a third- 
generation cephalosporin with similar in vitro anti- 
bacterial activity, except for better activity against 
Streptococcus pneumoniae and enhanced antistaphylo- 
coccal activity, a similar long elimination half-life as 
ceftibuten, but a rather low maximal serum concen- 
tration compared to other oral cephalosporins [2,9,12]. 
It has an absorption rate of about 50% [13]. Besides the 
fkaction of active drug entering the bowel, significant 
amounts of the prodrug would be expected to reach the 
colon and change the fecal flora in case of activation, 
i.e. de-esterification by intestinal esterases. Neverthe- 
less, in clinical trials the reported incidence of diarrhea 
with cefpodoxime proxetil is low [ 14-1 61, which is also 
the case for ceftibuten [17-191. 
The impact of amoxycillin/clavulanate, one of the 
most fkequently used broad-spectrum antimicrobial 
agents, on the gastrointestinal tract is frequent, so that 
it was used in our study as 'positive control'. Clinical data 
are inconsistent concerning the incidence of diarrhea 
with amoxycillin/clavulanate. There are several studies 
reporting a much higher incidence of diarrhea in 
clinical trials with amoxycillin/clavulanate than with 
ceftibuten and ceeodoxime proxetil [20-221. Alterna- 
tively, a few studies have shown a low incidence of loose 
stools with amoxycdldclavulanate, or have not shown 
any important difference [23,24]. Previous studies have 
shown that amoxycillin/clavulanate causes alterations 
in the normal flora [25-281. 
This study was performed in an open randomized 
triple crossover fashion to examine the pharmaco- 
lnetics of ceftibuten, cefpodoxime proxetil and 
amoxyc&n/clavulanate following multiple dosing over 
7 days in 18 normal volunteers. Furthermore, this 
design was chosen for a novel statistical approach to 
analyzing changes in fecal flora. Previous evaluations of 
fecal flora have not addressed the problem of statistical 
significance. For this study, the objective was not only 
the evaluation of the differences in fecal flora during 
treatment with a single antibacterial drug, but the 
statistically meaningful comparison of all three drugs in 
the same volunteers. With each volunteer serving as 
their own control for each microorgnism analyzed, 
and maintaining the comparison of effects within the 
same person, variability was reduced to a minimum, as 
interindividual baseline differences were eliminated. By 
calculation of an area under the curve (colony-forming 
units/g feces versus time) for each microorganism, 
standard tests allowed a statistical comparison of fecal 
flora changes in this relatively small study population. 
MATERIALS AND METHODS 
Study design 
This open randomized triple crossover study was 
designed to examine changes in fecal flora and pharma- 
colnetics with the three oral antibiotics ceftibuten, cef- 
podoxime proxetil and amoxycillin/clavulanate during 
and following 1 week of dosing in normal volunteers. It 
was not blinded, for technical reasons such as amount of 
medication and bioequivalence of formulated blinded 
medcation, because of the principal aims of studying 
fecal flora and pharmacokinetics, which are not 
influenced by an unblinded design, and in order to 
facilitate sampling for drug concentration. It was 
conducted from October 1992 to March 1993. The 
protocol was approved by the ethics committee of the 
Freie Universitat of Berlin, Germany. Medication intake 
was directly observed in each volunteer on day 1, and on 
the mornings of day 2 and day 7; all other medication 
had to be confirmed directly by telephone calls fkom 
the volunteer to the responsible physician, and each 
volunteer recorded a diary protocol with exact time of 
each medication, possible adverse event, and stools, 
including the quality of feces. All diaries were checked 
for possible differences with the protocol made when 
receiving the phone calls. In case of adverse events, the 
volunteers were asked to contact immediately the 
investigating physician, who performed a precise inter- 
view, and, if necessary, performed or organized consul- 
tations or further diagnostic or therapeutic procedures. 
Volunteers 
Eighteen healthy volunteers aged between 18 and 50 
years-nine non-pregnant females with a proven barrier 
method of contraception, and nine males-were 
randomly assigned to the study. Written informed 
consent was given after f d  explanation of the protocol. 
The mean age was 33.1 years (SD 5.7 years; range 
22-42 years). Mean height was 175 cm (SD 10 cm; 
range 157-190 cm). Mean weight was 71.9 kg (SD 10.2 
kg; range 56-90 kg). Mean creatinine clearance was 
117 mL/min (SD 23 mL/min; range 82-171 d / m i n ) .  
Volunteers with a hypersensitivity or serum sickness 
in response to any 0-lactam drug were excluded, as 
were volunteers taking dlicit drugs or any medication 
within 1 week of study entry or during the study, 
volunteers who had used antimicrobial drugs within 1 
month of study entry, volunteers with diarrhea, loose 
stools, or current or recent gastrointestinal disease, 
volunteers who had recently traveled to areas endemic 
for gastrointestinal parasites, or volunteers who had 
undergone recent hospitalization for any reason, in 
order to eliminate volunteers potentially colonized 
with resistant organisms. 
H a m a c h e r  et  a l :  F e c a l  f l o ra  a n d  p h a r m a c o k i n e t i c s  i n  t h ree  o r a l  D - l a c t a m s  3 4 1  
Antibiotic dosage and administration 
The test subjects received each oral study drug for 
7 days (ceftibuten 400 mg PO daily; amoxycillin/ 
clavulanate 500/125 mg every 8 h; cefpodoxime 
proxetil 200 mg every 12 h), followed by a 'washout' 
period of 4 weeks after each drug administration 
period. As the study was performed in a randomized 
triple crossover mode, the subjects were randomized to 
the six possible sequences (permutations) of study drug 
order. After three administrations and two washout 
periods, each subject had received the three different 
medications. 
Sampling 
Stool samples 
Fecal samples were collected twice per week before 
each of the three study drug administration periods, on 
the fourth day of medication, on the seventh (last) day 
of medication, on the eighth day (the first day after end 
of medication), and on days 12, 21 and 28 in the 
washout period. Samples of approximately 5 g each 
were collected in sterile plastic containers and were 
frozen in a -70°C freezer until analysis was performed. 
Blood samples 
These were taken repeatedly for serum drug level 
determination on days 1 and 7 after 0, 30, 60, 120, 240, 
and 360 min, the last sample being taken at 8 h (volun- 
teers under amoxycillin/clavulanate) and 12 h (volun- 
teers under cefiibuten and cefpodoxime proxetil). 
Urine 
This was analyzed on days 1 and 7. On both days, urine 
samples were analyzed from the periods 0-6 h and 
6-12 h for ceftibuten and cefpodoxime, 12-24 h for 
ceftibuten and 0-8 h for amoxycillin/clavulanate. 
Methods 
Analysis of the fecal flora 
Microbial identification and quantification was done 
according to colonial morphology, Gram stain, and 
various serologic and biochemical tests. A 1-g sample 
of stool was homogenized in 9 mL of prereduced 
peptone yeast extract medium. Tenfold serial dilutions 
were made to a dilution of' lo-*. The samples were 
inoculated and a quantitative estimate of each microbial 
species was made as described by Heimdahl and 
Nord [29]. All manipulations of the anaerobic bacteria 
were carried out in an anaerobic chamber (Forma, 
Philadelphia, PA, USA) under 10% (vol/vol) hydrogen 
in nitrogen. After 24 h (aerobic agar plates) or 48 h 
(anaerobic agar plates) of incubation at 37"C, total 
colony counts were determined from aerobic and 
anaerobic blood agar plates. Different colony types 
were counted, isolated in pure culture, and identified, 
as were the different colonies appearing on the selective 
media. All fecal samples were also assayed for yeasts,. 
Clostridiuni d f i c i l e  was searched for, and its toxins were 
determined by, a tissue-culture assay with human 
embryonic intestinal cells and a control with specific 
neutralizing antiserum, a method described by 
Aronsson et a1 [30]. Counts were given as log number 
of bacteria/g feces. 
Samples were assayed for p-lactamase activity using 
the chromogenic cephalosporin nitrocefin as substrate 
for a spectrophotometric determination of activity, as 
previously described [31,32]. One unit of P-lactamase 
was defined as the amount which formed 1.0 pmol of 
product per minute under given conditions. 
Bioassay 
The concentrations of the four substances in the serum 
and urine samples were determined with an agar 
diffusion bioassay (cup plate method), as modified by 
Reeves and Bywater [33] (Table 1). Serum and urine 
saniples were assayed in triplicate, and five standard 
concentrations (in triplicate) were used on each plate. 
Assay of ceftibuten in serum and urine by high-performance 
liquid chroma tograph y (HPL C) 
After addition of the internal standard toluenesulfonic 
acid, ceftibuten was extracted from serum with 
acetonitrile. Acetonitrile was back-extracted from the 
liquid phase with dichloroniethane. The aqueous 
supernatant was chromatogaphed on a reversed-phase 
column (Nucleosil 5C18, 125 mm (length), 4 mm 
(diameter); Macherey & Negel, Diiren, Germany). 
The mobile phase was acetonitrile/methanol/water 
(130:20:850) containing 3.4 g tetrabutylammonium 
phosphate, adjusted to pH 6.95 with 2 M sodium 
hydroxide solution. The absorbance of the eluate was 
monitored at 256 nm. Retention times were 8.5 min 
(cis-ceftibuten), 10.2 min (trans-ceftibuten) and 17.7 
min (internal standard). Urine was diluted with mobile 
phase before chromotography. Validation of the method 
yielded the following results for serum (urine): detection 
limit 0.1 mg/L (5.0 mg/L), lower limit of quantifi- 
cation 0.2 mg/L (10.0 mg/L, linear range 26.0 mg/L 
(1000 mg/L), coefficient of variance between series 
4.4-9.5% (2.1-4.9%), and recovery of 97.3-98.3% 
(1 07.3%). 
Statistical fecal flora analysis 
Each volunteer acted as his or her own control. 
Separate analyses were performed for each of the 
organisms. The cultures obtained at the latter of the 
two screening visits were used as the baselines. Change 
from baseline was analyzed to estimate differences in 
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Table 1 Characteristics of the bioassays 
Lower limit of Variation 
detection (mg/L) coefficient (%) 
Standard Bacterium Pool Pool 
Substance solution (test strain) Agar Buffer serum Buffer serum 
Ceftibuten (lot no. Sorensen’s buffer Morganella morganii DST agar 0.058 0.116 3.90 4.57 
28’173/001) at pH 7.2 I F 0  3848 
(DSM 30164) 
Cefpodoxime Sorensen’s buffer Morganella morganii Antibiotic 0.058 0.116 6.27 5.40 
(lot no. 18) at pH 7.2 I F 0  3848 medium 2 
(DSM 30164) Oxoid 
Amoxycillin Citrate buffer Bacillus subh’lis Antibiotic 
(batch no. 28) at pH 7.2 ATCC 6633 medmm 2 
Micrococcus Oxoid 
luteus 
ATCC 8340 
0.116 0.116 6.95 4.25 
0.010 0.030 5.40 3.28 
Cladanate Sorensen’s buffer Klebsiella CLED Agar with 0.030 0.058 6.42 3.04 
(batch no. 54) at pH 7.0 aerogenes Na-benzylpenicillin 
NCTC 11228 (Ch.B.OY 8007) 
the effects between the three study medications at each 
time point (days 4, 7, 8, 12, 21 and 28) for each 
organism. All statistical testing was performed at the 
p level of 0.05. 
As the subjects were randomized to one of the six 
possible treatment sequences that can be followed with 
three drugs, there were three subjects in each treatment 
sequence. Since one subject discontinued prematurely, 
she was excluded from statistical fecal flora analysis and 
replaced by a female volunteer who finished the whole 
study and was therefore included in the analysis 
according to the protocol. In order to include the 
repeated measures of the microbe counts at the six time 
points after baseline, the area under the curve (AUC) 
change from the baseline for every subject was 
calculated, working with loglo (colony-forming units 
microbedg feces) values. Using this transformed 
variable, differences from baseline were computed for 
each subject. Because the loglo transformations were 
used, differences were used, as opposed to ratios. This 
was performed for each treatment, so that a subject had 
three values for each time point concerning each 
microorganism. The AUC was computed for each 
treatment and each subject (so each subject had three 
AUC values concerning each microorganism). These 
AUC values were used for analyses. The between- 
treatment Merences were tested using a 3 x 3 crossover 
ANOVA model, with a p-value <0.05 being con- 
sidered as significant [34,35]. The ANOVA model 
included effects for sequence, subjects nested in 
sequence, period, treatment, and carryover. 
Pharmacokinetic calculations 
The main pharmacokinetic parameters were standard- 
ized to 70-kg body weight (area, C,,, volume of 
distribution in the steady state, divided by the oral 
bioavailability (L&/’) or to 1.73-m2 body surface 
area; (Cltot/’ CIRn). They were calculated model 
free (AUDtot, mean residence time (MRT), E-MRT 
(percentage of eliminated substance until MRT), C,,, 
V,/’ total and renal clearance (Cltot/’ Clm), as well as 
assuming an open one-compartment model (AUCr0, 
T, tsonp)). The calculations were performed by 
standard methods [36]. Differences in determined para- 
meters were analyzed for single variables by painvise 
t-test, and for multiple variables by multiple painvise 
comparisons according to Wilcoxon and Wilcox [37]. 
A p-value <0.05 was considered significant. 
RESULTS 
Tolerance 
One volunteer (female, 27 years) was replaced during 
the first study period because of fever, severe headache, 
leukocytosis (16.2 x 109/L with 4% eosinophils) and 
diarrhea after 5 days of medication with cefiibuten (no 
Clostridium d@ile or toxins were found). According to 
the protocol, the data of that volunteer were excluded 
from the final pharmacokinetic and fecal flora statistical 
evaluation. 
Further adverse events are listed in Table 2. 
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laboratory ehemicalleiinical parameters 
Aspartate aminotransferase (ASAT), alanine amino- 
transferase (ALAT), alkaline phosphatase, bilirubin, 
lactate dehydrogenase (LDH), protein, urea, creatinine, 
glucose, sodium, potassium, hemoglobin, hematocrit, 
white blood cell count including differential, platelet 
count, urinary glucose, protein, microscopic examina- 
tion and Coombs test were within normal limits on the 
first and last day of each treatment period of all volun- 
teers except the volunteer excluded as described above. 
Microbiological results 
Descriptive analysis of fecal flora 
The overview of the data in Figure 1(A-C) represents 
microorganism numbers per gram dry feces. 
During amoxycillin/clavulanate administration 
(Figure lC), there was no significant change in the 
aerobic fecal microflora. There was marked increase of 
yeasts (lo2 -lo4, nine volunteers) during treatment, 
with rapid normalization by day 12. In anaerobic 
bacteria, a slight increase of clostridia on days 8 (lo5), 
12 (lo6), and 21 (lo5) compared to premedication 
number (lo4) was seen; Clostridium dficile was detected 
in six volunteers, whereas its toxin was found in five of 
those s i x ;  all six had loose stools (but six of 11 volunteers 
had loose stools without having Clostridium df i i l e  or 
toxins in their stool samples). 
During ceftibuten administration (Figure 1 A), the 
aerobic microflora showed a marked increase of entero- 
cocci (2 x lo5 to 5 x lo7) and a marked decrease of 
E. coli (lo5 to 4 x 10'). In the anaerobic spectrum, a 
slight decrease of anaerobic cocci was observed. There 
were three patients harboring yeasts in feces, all three 
developing vaginitis beginning 1-2 days after termina- 
tion of study drug medication and requiring medical 
treatment. Clostridium d@le was found in s i x  volunteers 
during treatment, and its toxin in three of them, but 
none developed loose stools. 
Cefpodoxime proxetil (Figure 1B) also caused a 
marked increase of enterococci (4 x lo4 to lo7), but 
no change of E. coli. In the anaerobic spectrum, a slight 
decrease of anaerobic cocci was seen on day 4 only. 
Nine of the volunteers had Clostridium d@cile in their 
stools, five of them with toxin. None of them 
developed loose stools, but another volunteer did. 
Statistical analysis of the differences between the three 
antibiotics 
The ANOVA model did not show any effect by 
sequence, subjects nested in sequence, period, treat- 
ment, or carryover. 
E. coli levels were significantly higher with amoxy- 
cillin/clavulanate than with ceftibuten on days 7 and 8 
(p=0.002 and 0.01, respectively), which was also the 
case for amoxycillin/clavulanate and cefpodoxime 
proxetil on day 7 (p=0.008), but without significant 
overall change as determined by the AUC (~'0.29 and 
0.31). There was no significant difference between 
ceftibuten and cefpodoxime proxetil concerning E. coli 
changes. 
Significantly higher numbers of Klebsiella spp. were 
found on days 7 and 8 under arnoxycdldclavulanate 
than under ceftibuten as well as cefpodoxime proxetil 
(pc0 .05  each). Again, there was no difference between 
ceftibuten and cefpodoxime proxetil. 
Significantly higher numbers of enterobacteria 
(Enterobactericeae excluding E.  c o g  were found with 
amoxycillin/clavulanate than with ceftibuten on days 7 
and 8, as well as with cefpodoxime proxetil on day 8 
(pc0 .05  each), again without a difference between 
ceftibuten and cefpodoxime proxetil. 
There were significantly less enterococci found 
with amoxycdin/clavulanate than with ceftibuten on 
days 4 ,7  and 8 and in the AUC (p~0.006,0.003,0.008 
and 0.02, respectively). There were also significantly 
less enterococci found with amoxycillin/clavulanate 
than with cefpodoxime proxetd on days 4, 7, and 8 
(p<0.05 each), but not in the AUC (p=0.09). Again, 
no significant difference was found between ceftibuten 
and cefpodoxime proxetil. 
Significantly higher Candida albicans fecal concen- 
trations were found with amoxycdldclavulanate than 
with ceftibuten on days 4, 7 and 8 and in the AUC 
between ceftibuten and amoxycilldclavulanate (p<0.05 
each), whereas the differences between amoxycillin/ 
clavulanate and cefpodoxime proxetil did not reach 
significant levels. There was no significant hfference 
between ceftibuten and cefpodoxime proxetil. 
Significantly less Bacteroides spp. as well as 
Lactobacillus spp. were found only on day 7 during 
the amoxycillin/clavulanate study period, but not 
with either cephalosporin (p<0.05 each). Again, there 
were no merences between cefbbuten and ce$odoxime 
proxetil. 
No significant differences were found for Bijdo- 
bacterium spp., anaerobic cocci, aerobic Gram-positive 
rods, Clostridium spp., Staphylococcus aureus, group A 
streptococci, group B streptococci, Eillonella spp., 
Citrobacter spp., Proteus spp., Actinomyces spp., Staphylo- 
coccus epidermidis, Micrococcus spp., Clostridium perfringens, 
Fusobacterium spp., Eubacterium spp., Bacillus spp., aerobic 
Gram-negative rods, and fungi. 
Apart from higher numbers of Clostridium spp. 
on day 21 with amoxycillin/clavulanate than with 
ceftibuten (p=O.O2), significant differences were never 
found between the three antibiotics on days 12, 21 and 
28, even when significant results were obtained during 
treatment in all the bacteria and yeasts analyzed. 
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The only significant difference found between 
ceftibuten and cefpodoxime proxetil was in Eubacterium 
spp. on day 4 (p=0.016), with higher CFU/g feces 
under ceftibuten. 
J- 
P-Lactamase activity in feces 
P-Lactamase activity was found in baseline stools of 
each treatment period in s i x ,  four, and eight of the 18 
volunteers (Table 3). At the end of treatment (day 7/8), 
P-lactamase was seen in two more volunteers under 
ceftibuten, as it was at the end of the washout period 
(days 21-28). With cefpodoxime proxetil, the p-lacta- 
mase activity was seen in 10 more volunteers (14/18) 
under treatment, reducing to nine volunteers after 
21-28 days. After amoxyciUin/clavulanate medication, 
there was an increase of p-lactamase activity fiom eight 
to 17 of 18 volunteers, and a reduction to eight of 18 
volunteers in the samples of days 21-28 (five being 
other volunteers than those with initial activity). In this 
group, one volunteer had loose stools but never had 
P-lactamase activity demonstrated in this medication 
period. In conclusion, and as best demonstrated in 
Table 3, there seems to be a trend to more P-lactamase 
activity at the end of amoxycillin/clavulanate treatment 
and a more marked increase under cef$odoxime proxetil 
administration than under ceftibuten administration. 
Loose stools were not always associated with p-lacta- 
mase activity (volunteer 17 under cefpodoxime proxetil 
having neither p-lactamase activity, nor yeasts in stool, 
Table 3 P-Lactamase activity in U/g feces” 
and volunteer 3 under amoxycillin/clavulanate having 
yeasts in all stools). 
Pharrnacokinetics 
The main pharmacokinetic parameters were standard- 
ized to 70 kg body weight. They are given in Table 4. 
Figure 2 shows the median and standard ranges of 
cis-ceftibuten and trans-ceftibuten, respectively, on day 
1 after oral 400 mg ceftibuten every 24 h in 18 volun- 
teers. The values are normalized to a body weight of 
70 kg. 
0.03 1 . , . , , , . , . 1 
0 2 4 6 8 10 12 
Time after oral application (h) 
Figure 2 Serum regression (-), median of cis-ceftibuten 
and trans-ceftibuten (.) and standard range in serum after 
oral 400 mg ceftibuten every 24 h in 18 volunteers on day 
1. Values are normalized to a body weight of 70 kg. 
Cefpodoxime Amoxycillin/ 
Ceftibuten proxetil clavulanate 
Days 7 Days Days 7 Days Days 7 Days 
Volunteer no. Day 0 and 8 21-28 Day0 and8 21-28 Day 0 and 8 21-28 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
0.336 
0.570 
0 
0 
0.262 
0 
0 
1.615 
0 
0 
0 
0 
0 
0 
1.71 
0 
0 
0.735 
0.855 
3.135 
0 
0 
0.938 
0 
0 
1.243 
0.014 
0.171 
0 
0.120 
0 
0 
0.137 
0 
0 
0 
1.881 
0.251 
0.040 
0 
0.182 
0 
0 
1.425 
0.150 
0 
0 
0.703 
0 
0 
3.192 
0 
0 
0 
0.057 0.741 
0.698 2.508 
0 2.138 
0 0.186 
0.308 1.744 
0 0 
0 0 
0 0.399 
0 0.314 
0.105 0.162 
0 4.560 
0 0.715 
0 0.504 
0 0.684 
0 0.969 
0 0 
0 0 
0 0.148 
0.348 
1.505 
0 
0 
0.673 
0 
0 
0.245 
1.299 
0 
0.577 
0 
0 
0.182 
0 
0.128 
0 
0.673 
0.946 
1.870 
0 
0 
0.148 
0 
1.083 
0 
0 
0 
0 
0 
0 
0.160 
0.855 
0 
0.108 
0.099 
2.394 
4.788 
0 
1.208 
1.653 
0.074 
0.239 
0.755 
1.520 
0.091 
4.275 
1.505 
0.088 
0.257 
1.026 
0.177 
6.555 
0.122 
~~ 
2.337 
2.850 
0 
0.200 
0.299 
0 
0 
1.254 
0 
0 
1.226 
0.274 
0 
0 
1.550 
0 
0 
0.276 
’One unit is defined as the amount which formed 1.0 pmol of product per minute under the given conditions. 
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Table 4 Pharmacokinetic parameters 
Cefpodoxime Amoxycillin Clavulanate 
(200 mg (500 mg (125 mg 
Ceftibuten (4(!0 mg cis-Ceftibuten trans-Ceftibuten every 12 h) every 8 h) every 8 h) 
Parameter every 24 h) (bioassay) (HPLC) (HPLC) (bioassay) (bioassay) (bioassay) 
c,,lax (mg/L) 18.9 (3.0) 18.1 (4.3) 3.39 (1.20) 1.92 (0.61) 7.15 (2.16) 3.38 (1.73) 
21.2 (5.3)" 
Tmx (h) 2.07 (0.55) 2.20 (0.63) 2.26 (0.66) 2.23 (0.35) 1.35 (0.24) 1.32 (0.37) 
1.60 (0.38)" 1.43 (0.34)" 
t m p  ih) 2.89 (0.61) 2.50 (0.62) 1.92 (0.30) 1.97 (0.42) 1.03 (0.15) 0.93 (0.17) 
2.39 (0.30)" 
AUCm, (mg/h/L) 100.0 (21.8) 82.23 (18.48) 14.0 (4.0) 10.8 (3.3) 20.0 (4.2) 8.87 (3.10) 
115.0 (26.4)b 
MRT (h) 4.22 (0.35) 4.02 (0.33) 3.93 (0.43) 3.89 (0.43) 2.34 (0.18) 2.25 (0.30) 
2.77 (0.48)' 
L<JJ (1/70 kg) 11.5 (1.6) 13.55 (2.68) 64.9 (24.9) 48.4 (15.3) 39.6 (11.2) 22.2 (7.0) 
9.6 (3.9)" 17.48 (7.09) 47.9 (11.1)6 
Ur.f (Yo) 60.8 (19.3) 55.91 (17.45) 13.6 (6.9) 46.3 (16.5) 48.8 (1 1.0) 20.0 (10.5) 
CL"t if 
C1,n 39.1 (10.6) 46.91 (17.44) 69 (34) 139 (36) 187 (57) 45.5 (23.7) 
(mL/min/1.73 m') 66.9 (17.5) 85.39 (23.81) 527 (179) 331 (128) 388 (98) 240 (77) 
(mL/min/l.73 m2) 37.92 (8.92)" 61.4 (39.6)" 
Mean (standard deviation) for day I ,  and for day 7 only when significantly different (p<0.05; Wilcoxon or Wilcoxon-Wilcox, respectively; 
marked as "p<0.05; bp<O.Ol; cp<lS.OO1). 
C,, AUC,,, and I:,/Jare calculated for dose/70 kg body weight. 
Oral bioavailabihty is indicated byj: C,,,,, maximum concentration; T,, time to maximum concentration; t l/zp, elimination half-life; 
AUC,,,, area under the curve; MKT, mean residence time; KS/J volume of distribution in the steady state, divided by the oral 
bioavailability, corresponding to rate of metabolism; Ur.f, urinary recovery multiplied by oral bioavailability; Cltot/J total clearance, divided 
by oral bioavailability; Cl,,,, renal clearance 
Figures 3-5 show the corresponding median and 
standard ranges of serum concentrations of the four 
study drugs in the 18 volunteers, standardized to a body 
weight of 70 kg. 
On comparison of the results of ceftibuten based 
on HPLC with those determined by bioassay, no sig- 
nificant differences in the pharmacokinetic parameters 
were found (two-sided Wilcoxon-Wilcox test [37]). 
DISCUSSION 
Despite the many similar indications for oral amoxy- 
cillin/clavulanate, ceftibuten. and cefpodoxime proxetil, 
there are important differences in their pharmaco- 
kinetic profiles as well as in their impacts on fecal flora. 
Compared with amoxycillin, the half-life of ceftibuten 
was about 2.8 times longer, and that of cefpodoxime 
two times longer (1.03 h), and the areas under the 
curve were five times larger with ceftibuten, and about 
50% smaller with cefpodoxirne. More meaningfully the 
ratio of AUC and dose per 24 h for ceftibuten was 
about 19 times higher, and in cefpodoxime about two 
times higher, than for amoxycillin. All three p-lactams 
were well absorbed, as evidenced by their intermediate 
to high urinary recovery. 
Ceftibuten shows a high protein binding rate of 
about 63%, which is higher than that of other new oral 
cephalosporins [2,10], high serum levels, and a longer 
half-life, resulting in the largest AUC. This is also the 
case for the whole group of new oral cephalosporins 
after correction for dose [5]. This pharmacokinetic 
profile allows twice-daily or even once-daily oral 
administration for treatment of several types of 
infections [4,38]. The significant 12% rise of C,, 
found after multiple dosage is consistent with the 13% 
rise described by Barr et a1 [39]. Accumulation reached 
significance only in model-derived statistics, not in 
model-free calculations, despite our rather high numbers 
of subjects tested. The levels of the eightfold less 
antibacterially active trans-ceftibuten isomer [39] in 
serum were about two to three times higher (15.1% of 
total cefiibuten, or 17.8% of cis-ceftibuten) than 
described in plasma [39-411; this might be partly due 
to cis-trans interconversion during sample processing to 
serum. 
Cefpodoxime is characterized by low serum levels, 
a moderately long elimination half-life and late T,,,, 
allowing twice-daily dosing 1421, and a much lower 
protein binding of 18-23% compared to ceftibuten 
[43]. There is no evidence of accumulation [43-451. 
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Time after first oral dose (days) 
Figure 3 Serum concentrations (median and standard ranges) on day 1 and day 7; regression and simulation based on day 1 
data with oral 400 mg ceftibuten every 24 h in 18 volunteers. Values are normalized to a body weight of 70 kg. 
?=time between two drug administrations. 
Cefpodoxime proxetil; T = 12 h 
5 , j I , : I ~  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Simulation, based on day 1 data 
Data: day 1 (medianzstd range) 
Data: day 7 (medianzstd range) 
0.01 
0 1 6 7 
Time after first oral dose (days) 
Figure 4 Serum concentrations (median and standard 
ranges) on day 1 and day 7, regression and simulation based 
on day 1 data with oral 400 mg cefpodozime proxetil every 
12 h in 18 volunteers. Values are normalized to a body weight 
of 70 kg.   time between two drug administrations. 
0.05 1 E 
0 2 4 6 8 
Time after oral application (h) 
Figure 5 Serum regression (-) of amoxycillin 500 mg 
every 8 h and clavulanate 125 mg every 8 h (median and 
standard ranges) in 18 volunteers on day 1. Values are 
standardized to a body weight of 70 kg. 
Compared to published data from Saathoff et al [46] 
with 10 male volunteers and those of Trembley et al 
[47] with 12 volunteers, our data showed identical 
T-, but lower C,,, (1.92 versus 2.54 mg/L), and a 
shorter elimination half-life (1.97 versus 2.87 h), result- 
ing in a smaller AUCtOt (10.8 versus 14.0mg, h/L), 
which might be explained by differences in gender. 
As food intake augments the bioavailability of cephalo- 
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sporin esters [5,48,49] and decreases that of ceftibuten 
[39], the studies were performed after overnight fasting. 
Amoxycillin had ratheir high serum levels and 
clavulanic acid had intermediate serum levels and 
their short T, and half-life values were sirmlar 150-521. 
Neither substance accumulated [53]. The urinary 
recovery of 48.8% of amoxycillin was similar to that of 
cefpodoxime and other p-lactams. We found a lower 
than reported urinary recovlery of 20.0% (SD 10.5%) 
of clavulanic acid [50,51,53,54], which might be 
influenced by its temperature- and pH-dependent 
degradation [55-571. 
The major advantage of our triple crossover design 
using standard oral dosages and treatment durations was 
the ability to demonstrate drug-dependent fecal flora 
alterations with statistical means rather than by descrip- 
tive analysis. The crossover design was also aimed at 
circumventing interpersonal variations of the gastro- 
intestinal microflora, by being based on the intra- 
personal fecal flora, which is assumed to be remarkably 
stable [58,59]. Changes of the ecosystem due to an 
antimicrobial agent depend on its antibiotic spectrum, 
route of administration, dose, duration, and pharmaco- 
kinetic properties such as incomplete absorption, 
secretion in bile or through intestinal mucosa, activ- 
ation of prodrugs, or inactivation, e.g. with microbial 
and sometimes pre-existing P-lactamases [l  1,59-611, 
or by drug binding to fecal macromolecules [62]. 
Nearly 40% of orally administered radiomarked 
cefiibuten is found in feces [39]. In spite of this appar- 
ently important intestinal exposure, very low bioassay- 
determined fecal concentrations were described, as 
detectable levels were found in only two of 14 
volunteers, neither having any P-lactamase activity 
under 400 mg/24 h during 10 days in the study of 
Brismar et al [ l l] .  Of the prodrug ester cefpodoxime 
proxetil, about half of the d.ose normally stays in the 
intestine. The other half gets absorbed and activated 
with de-esterification by non-specific esterases of the 
intestinal epithelium, and not in the lumen [13,63]. 
Although cleavage of the ester might take place in the 
intestine, there seems to be an important degradation 
of the compound to <0.5% of the administered dose 
[63]. However, fecal antibiotic activity seems to differ 
considerably, as Edlund et a1 1[60] found measurable and 
quite high cefpodoxime amoiints with a bioassay in only 
three of 10 volunteers. Fecal amoxycillidclavulanate 
was below the limit of detection in a study from 
Brumfitt et a1 [28]. Amoxycillin/clavulanate, used as a 
‘positive control’ concerning fecal flora effects in our 
study, induced significantly more pronounced changes 
of the fecal flora, and caused considerably more 
gastrointestinal side effects, mainly in terms of reported 
loose stools. According to the antibacterial spectrum, 
significantly more suppression of Bacteroides spp., 
lactobacilli and enterococci was found during amoxy- 
cillin/clavulanate treatment than with the new 
cephalosporins; on the other hand, the numbers of 
enterobacteria, including E. coli, Klebsiella spp., and 
Candida albicans, were higher. P-Lactamase activity 
either on day 7 or day 8 was found in eight volunteers 
with ceftibuten, in 14 with cefpodoxime proxetil, and 
in virtually all (17/18) with amoxycillin/clavulanic 
acid, despite its P-lactamase inhibitor component, 
whereas 0-lactamase was found in four to eight 
volunteers in the fecal samples before study drug 
administration. 
Our data differ from those of Todd and Benfield 
concerning the high prevalence of Clostridium d&cile 
[64] found in one-third to one-half of our volunteers: 
in six under ceftibuten and amoxycillin/clavulanate 
administration and in nine under ce@odoxime proxetil 
administration, about half of them being toxigenic. Our 
results confirm others showing that neither Clostridium 
d@cile and its toxins, nor yeasts, are closely associated 
with loose stools [60,65-67], which is also the case with 
p-lactamase activity. They underline the more complex 
pathogenesis of antibiotic-associated diarrhea. 
In our unblinded study, 11 of 18 volunteers (61%) 
under amoxycillin/clavulanate reported a mean of 11 
loose stools over 4.4 days. The episode started in nine 
of the 11 volunteers between day 1 and day 4, suggest- 
ing very early causative changes that might therefore 
not be avoidable by shortening the time of treatment. 
The very high incidence of loose stools with amoxy- 
cillin/clavulanate contrasted with only one volunteer 
(5.6%) having loose stools under cefpodoxime proxetil, 
and with none under cefiibuten. 
In terms of symptoms, our 61% incidence of loose 
stools contrasted also with the approximately 3.5% 
diarrhea reported in more than 32 000 patients studied 
with amoxycillin/clavulanate by Neu et a1 [24] and the 
4.1% of 9700 patients reviewed by Croydon [68]. They 
reported a maximal incidence of about 6% if no 
specified gastrointestinal events were included, and this 
is in the range reported for cefpodoxime proxetil 
[14-161 and ceftibuten [17]. This raises the question of 
why the reported incidence of loose stools or diarrhea 
under amoxycillin/clavulanate varies between extremes 
in the literature, reaching 34% in one large children’s 
acute otitis media study [20]. Besides the hampering 
lack of a simple and clearcut definition of diarrhea, the 
different dosing and treatment schedules and applic- 
ation modes, the heterogeneity of the treated patient 
groups, and the clinicians and investigators focusing on 
other findings than loose stools, might be the most 
important biases in studies not primarily addressing this 
question. One drawback of our study focused on stool 
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changes is its unblinded design, with the stool changes 
data being based on volunteers’ reports. 
Despite the fact that more volunteers had yeasts in 
their stools under amoxycillidclavulanate than under 
the two cephalosporins, all three probable candida 
vaginitis episodes occurred 1-2 days after ceftibuten 
medication, a side effect also described in one patient 
in the study of Stein et al [17]. This side effect occurred 
after the third investigation period, suggesting that a 
prolonged and more complex disruption of the vaginal 
flora may have occurred. 
In conclusion, ceftibuten shows comparatively 
favorable, and cefpodoxime proxetil good, pharmaco- 
kinetic properties after oral administration, allow- 
ing longer dosing intervals than with amoxycillin/ 
clavulanate. The statistically confirmed more discrete 
ecological disturbances of the fecal flora by ceftibuten 
and cefpodoxime may be due to low concentrations of 
the substances [63] or to the substances being found 
only in a few persons in feces [11,60], whereas amoxy- 
cillin/clavulanate is found in considerable amounts in 
feces [26,59]. Their narrower antimicrobial spectrum 
compared to amoxycillin/clavulanate may contribute 
to less pronounced flora changes. These pharmaco- 
kinetic and microbiological observations are consistent 
with the clinical observations of much less frequent 
intestinal side effects with the dosages used [20-22,691. 
The multiple crossover design, calculating an area 
under the time curve for the log count of each micro- 
organism, allows microbiological changes not only to 
be described, but also to be statistically analyzed, thus 
extending the utility of study results. 
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